For Q1 FY2026 ended March 31, 2026, Hemab Therapeutics reported a net loss of $22.7 million, a 48.2% increase from the prior year. Operating loss was $23.6 million, up 42.6% year-over-year. Diluted EPS was -$23.98, compared to -$16.18 a year ago. The company had $49.9 million in cash and negative equity of $198.6 million.
•Net loss widened 48.2% to $22.7 million.
•Operating loss increased 42.6% to $23.6 million.
•Diluted EPS was -$23.98, a 48.2% decline year-over-year.
•Cash balance stood at $49.9 million with negative stockholders' equity of $198.6 million.
Informational summary based on SEC XBRL figures · generated by deepseek-v4-flash. Not investment advice.
Hemab Therapeutics is a clinical-stage biotechnology company developing therapies that reimagine the treatment of blood coagulation disorders to sustain life and human resilience in United States of America and Denmark.
Its products includes (HMB-001), is a bispecific antibody currently in Phase 1/2 clinical development for the prophylactic treatment of Glanzmann thrombasthenia and Phase 2 clinical development for the prophylactic treatment of Factor VII deficiency
Second clinical-stage asset, HMB-002, is a monovalent antibody in Phase 1/2 clinical development for the subcutaneous prophylactic treatment of Von Willebrand disease. It also advances multiple preclinical and discovery-stage assets. Founded in 2020, the company is based in Cambridge, Massachusetts.
Hemab Therapeutics is a clinical-stage biotechnology company focused on developing therapies for blood coagulation disorders. Its lead product, HMB-001, is a bispecific antibody in Phase 1/2 clinical development for the prophylactic treatment of Glanzmann thrombasthenia and in Phase 2 for Factor VII deficiency. The second clinical-stage asset, HMB-002, is a monovalent antibody in Phase 1/2 for subcutaneous prophylactic treatment of Von Willebrand disease. The company also has multiple preclinical and discovery-stage assets. Hemab aims to reimagine the treatment of bleeding disorders to sustain life and human resilience.
Where is Hemab Therapeutics (COAG) listed and in which currency?
Hemab Therapeutics is listed on the Nasdaq Global Select Market (NasdaqGS) under the ticker symbol COAG. The company's financials are reported in US Dollars (USD), as it is based in the United States. The exchange and currency reflect its primary listing in the US equity markets, making it accessible to investors trading on Nasdaq.
What sector and industry does Hemab Therapeutics (COAG) operate in?
Hemab Therapeutics operates in the Healthcare sector, specifically within the Biotechnology industry. As a clinical-stage biotech company, it focuses on developing innovative therapies for blood coagulation disorders. Biotechnology companies like Hemab engage in research and development of drugs, often with a high-risk, high-reward profile, targeting unmet medical needs in areas such as rare bleeding disorders.
Where is Hemab Therapeutics (COAG) headquartered and what markets does it serve?
Hemab Therapeutics is headquartered in Cambridge, Massachusetts, United States. The company operates in the United States and Denmark, as indicated in its description. It serves patients with blood coagulation disorders, including Glanzmann thrombasthenia, Factor VII deficiency, and Von Willebrand disease. Its therapies are being developed for prophylactic treatment, aiming to address unmet needs in both US and international markets.
What are the main products in Hemab Therapeutics' (COAG) pipeline?
Hemab Therapeutics has two clinical-stage products. HMB-001 is a bispecific antibody in Phase 1/2 for Glanzmann thrombasthenia and Phase 2 for Factor VII deficiency, both for prophylactic use. HMB-002 is a monovalent antibody in Phase 1/2 for subcutaneous prophylactic treatment of Von Willebrand disease. Additionally, the company is advancing multiple preclinical and discovery-stage assets. These products target rare bleeding disorders, aiming to provide new treatment options for patients with limited existing therapies.